LG Life Science LTD (068870):企業のM&A・提携動向(医療分野)

【英語タイトル】LG Life Science LTD (068870) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(GDPH81941D)・商品コード:GDPH81941D
・発行会社(調査会社):GlobalData
・発行日:2017年2月17日
・ページ数:24
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
LG Life Science LTD (LGLS) is a global life science company that offers development, production and marketing of pharmaceutical products. The company provides pipeline of antibiotic, Factive and other drug candidates. Its products include vaccines, anti-infective, chemicals, veterinary medicine, fine chem, facial aesthetics, viscosupplements, products for hormones and fertility treatment. LGLS offers intermax gamma, intermax alpha, degenerative arthritis treatment, and others. The company’s target therapeutic areas include infectious disease, metabolic disease, urology, oncology, musculoskeletal, endocrinology, infertility, molecular diagnostics and others. It operates through its research center and plant, located in Korea. The company has operational presence in India, Poland, China and Jordan. LGLS is headquartered in Seoul, South Korea.

LG Life Science LTD (068870) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
LG Life Science LTD, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
LG Life Science LTD, Medical Devices Deals, 2011 to YTD 2017 9
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
LG Life Science LTD, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 11
Precision System Science Enters Into Distribution Agreement With LG Life Sciences 11
Chong Kun Dang Enters Into Distribution Agreement With LG Life Sciences For Uritos 12
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 13
Green Cross Enters Into Co-Promotion Agreement With LG Life Sciences For Shinbaro 14
Licensing Agreements 14
LG Life Sciences Enters into Licensing Agreement with Mochida Pharma 14
Ildong Enters Into Licensing Agreement With LG Life Sciences For Factive, Oral Quinolone Antibiotic 15
LG Life Sciences Enters Into License Agreement With Mochida For Biosimilar Antibody Drugs 16
LG Life Sciences Enters Into Licensing Agreement With Ildong Pharma For Besifovir 17
Novavax Enters Into Licensing Agreement With LG Life Sciences 18
LG Life Science LTD – Key Competitors 20
Key Employees 21
Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
LG Life Science LTD, Pharmaceuticals & Healthcare, Key Facts, 2015 1
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
LG Life Science LTD, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
LG Life Science LTD, Deals By Therapy Area, 2011 to YTD 2017 8
LG Life Science LTD, Medical Devices Deals, 2011 to YTD 2017 9
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 11
Precision System Science Enters Into Distribution Agreement With LG Life Sciences 11
Chong Kun Dang Enters Into Distribution Agreement With LG Life Sciences For Uritos 12
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 13
Green Cross Enters Into Co-Promotion Agreement With LG Life Sciences For Shinbaro 14
LG Life Sciences Enters into Licensing Agreement with Mochida Pharma 14
Ildong Enters Into Licensing Agreement With LG Life Sciences For Factive, Oral Quinolone Antibiotic 15
LG Life Sciences Enters Into License Agreement With Mochida For Biosimilar Antibody Drugs 16
LG Life Sciences Enters Into Licensing Agreement With Ildong Pharma For Besifovir 17
Novavax Enters Into Licensing Agreement With LG Life Sciences 18
LG Life Science LTD, Key Competitors 20
LG Life Science LTD, Key Employees 21
LG Life Science LTD, Other Locations 22
LG Life Science LTD, Subsidiaries 22

List of Figures
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
LG Life Science LTD, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
LG Life Science LTD, Medical Devices Deals, 2011 to YTD 2017 9

★調査レポート[LG Life Science LTD (068870):企業のM&A・提携動向(医療分野)] (コード:GDPH81941D)販売に関する免責事項を必ずご確認ください。
★調査レポート[LG Life Science LTD (068870):企業のM&A・提携動向(医療分野)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆